¹Division of Clinical Neuromodulation Research, Karma Doctors, Palm Springs, CA, USA
²Brown University School of Public Health, Providence, RI, USA
³University of California Irvine, CA, USA
⁴Palm Desert High School, Palm Desert, CA, USA
⁵KPC Healthcare, Hemet, CA, USA
⁶Sunder Foundation, Palm Springs, CA, USA
⁷Western University Health Science Centers, Graduate College, Pompano, CA, USA
⁸Department of Psychiatry, University of Vermont, Burlington, VT, USA
⁹Institute of Psychology, Eotvos Loránd University, Budapest, Hungary
¹⁰Department of Psychiatry, Wright University Boonshoft School of Medicine, Dayton, OH, USA
¹¹Centre for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology, Nonakuri, Purba Medinipur, West Bengal, India
¹²Department of Psychiatry, Stanford University School of Medicine, Palo Alto, CA., USA
¹³Division of Personalized Pain Therapy Research, Center for Advanced Spine Care of Southern Arizona, Tucson, Arizona, United States of America
¹⁴Department of Orthopaedics, Fundación Universitaria Sanitas, Bogotá, Colombia
¹⁵Department of Orthopedics, Hospital Universitário Gaffree Guinle Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
¹⁶Department of Psychiatry, Mt. Sinai University School of Medicine, New York, NY, USA
¹⁷Brain and Behavior Laboratory, Department of Psychology, Curry College, Milton, USA
¹⁸Department of Psychiatry, University of California Riverside School of Medicine, CA, USA

*Corresponding Author: Kavya Mohankumar, Division of Clinical Neuromodulation Research, Karma Doctors, Palm Springs, CA, USA.

Received: December 18, 2024; Published: January 24, 2025

Abstract

Personalized repetitive Transcranial Magnetic Stimulation (PrTMS^®) offers an individualized approach to neuromodulation through customized treatment protocols. This case series aims to explore therapeutic outcomes of PrTMS^® in two patients with post-traumatic stress disorder (PTSD), based on standardized rating scale scores and spectral EEG-guided alpha brainwave activity optimization. Participants diagnosed with PTSD received PrTMS^® treatments informed by quantitative rating scales and weekly spectral EEG measurements. Weekly psychometric assessments showed an improvement in symptoms, as quantified by PCL-5 (Posttraumatic Stress Disorder Checklist for DSM-5), GAD-7 (Generalized Anxiety Disorder 7-item scale), PHQ-9 (Patient Health Questionnaire-9), and SCI (Sleep Condition Indicator) questionnaires. Specifically, PCL-5 scores demonstrated an average reduction of 20.5 points by the midpoint of treatment (4 weeks), while GAD-7 and PHQ-9 scores decreased by 7 and 8.5 points, respectively, at the end of 7 weeks. Mean SCI scores increased by 6 points by the end of the 7 week-treatment period. While previous studies have also highlighted the role of spectral EEG-directed personalized PrTMS in the treatment of PTSD, ongoing research is needed in order to understand the long-term efficacy of PrTMS^®.

Keywords: Personalized Repetitive Transcranial Magnetic Stimulation (PrTMS^®); Repetitive Transcranial Magnetic Stimulation (rTMS); Neuromodulation; PTSD (Post-Traumatic Stress Disorder); Spectral EEG; Spectral Electroencephalogram; PCL-5 (Post-Traumatic Stress Disorder Symptom Severity Checklist for DSM-5); Alpha Brainwave Activity

References

1. Michopoulos V., et al. “Posttraumatic stress disorder: A metabolic disorder in disguise?” Experimental Neurology 284.Pt B (2016): 220-229.
2. Mayo Clinic Staff. “Post-traumatic stress disorder (PTSD)”. Mayo Clinic.
3. Angelakis S and Nixon RDV. “The Comorbidity of PTSD and MDD: Implications for Clinical Practice and Future Research”. Behaviour Change 32.1 (2015): 1-25.

4. Blum K., et al. “Understanding the scientific basis of post-traumatic stress disorder (PTSD): Precision behavioral management overrides stigmatization”. Molecular Neurobiology 11 (2019): 7836-7850.
5. Bowirrat A., et al. “Neuro-psychopharmacogenetics and neurological antecedents of posttraumatic stress disorder: Unlocking the mysteries of resilience and vulnerability”. Current Neuropharmacology 4 (2010): 335-358.
6. Blum K., et al. “Diagnosis and healing in veterans suspected of suffering from post-traumatic stress disorder (PTSD) using reward gene testing and reward circuitry natural dopaminergic activation”. Journal of Genetic Syndromes and Gene Therapy3 (2012): Article 1000116.
7. Blum K., et al. “Endorphinergic enhancement attenuation of post-traumatic stress disorder (PTSD) via activation of neuro-immunological function in the face of a viral pandemic”. Current Psychopharmacology 2 (2021): 86-97.
8. McLaughlin T., et al. “Putative dopamine agonist (KB220Z) attenuates lucid nightmares in PTSD patients: Role of enhanced brain reward functional (2015).
9. Gondré-Lewis MC., et al. “Pre-clinical models of reward deficiency syndrome: A behavioral octopus”. Neuroscience and Biobehavioral Reviews 115 (2020): 164-188.
10. Blum K., et al. “Reward deficiency syndrome (RDS) surprisingly is evolutionary and found everywhere: Is it "blowin' in the wind?” Journal of Personalized Medicine 2 (2022): 321.
11. Gold MS., et al. “Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti-reward systems”. Frontiers in Bioscience (Scholar Edition) 2 (2018): 309-325.
12. Comings DE and Blum K. “Reward deficiency syndrome: Genetic aspects of behavioral disorders”. Progress in Brain Research 126 (2000): 325-341.
13. Blum K., et al. “Epigenetic repair of terrifying lucid dreams by enhanced brain reward functional connectivity and induction of dopaminergic homeostatic signaling”. Current Psychopharmacology 10 (2021): Article 10.
14. Blum K., et al. “Dopamine dysregulation in reward and autism spectrum disorder”. Brain Sciences 7 (2024): 733.

1. Yesavage JA., et al. “Effect of repetitive transcranial magnetic stimulation on treatment-resistant major depression in US veterans: A randomized clinical trial”. JAMA Psychiatry 75.9 (2018): 884-893.
2. Kozel FA., et al. “Repetitive TMS to augment cognitive processing therapy in combat veterans of recent conflicts with PTSD: A randomized clinical trial”. Journal of Affective Disorders 229 (2018): 506-514.
3. Madore MR., et al. “Prefrontal transcranial magnetic stimulation for depression in US military veterans - A naturalistic cohort study in the veterans health administration”. Journal of Affective Disorders 297 (2022): 671-678.
4. Berlim MT and Van Den Eynde F. “Repetitive transcranial magnetic stimulation over the dorsolateral prefrontal cortex for treating posttraumatic stress disorder: An exploratory meta-analysis of randomized, double-blind and sham-controlled trials”. Canadian Journal of Psychiatry 59.9 (2014): 487-496.
5. Cohen H., et al. “Repetitive transcranial magnetic stimulation of the right dorsolateral prefrontal cortex in posttraumatic stress disorder: A double-blind, placebo-controlled study”. American Journal of Psychiatry 161.3 (2004): 515-524.
6. O'Reardon JP., et al. “Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: A multisite randomized controlled trial”. Biological Psychiatry 62.11 (2007): 1208-1216.
7. Stultz DJ., et al. “Transcranial magnetic stimulation (TMS) safety with respect to seizures: A literature review”. Neuropsychiatric Disease and Treatment 16 (2020): 2989-3000.
8. Makale MT., et al. “Personalized repetitive transcranial magnetic stimulation (PrTMS^®) for post-traumatic stress disorder (PTSD) in military combat veterans”. Heliyon 9.8 (2023).
9. Makale MT., et al. “Personalized repetitive transcranial magnetic stimulation guided by the spectral electroencephalogram may enhance and democratize therapy for autism spectrum disorder”. Medical Hypotheses (2024): 186.
10. Makale MT., et al. “Preliminary observations of personalized repetitive magnetic stimulation (PrTMS) guided by EEG spectra for concussion”. Brain Sciences 13.8 (2023): 1179.
11. Maia V., et al. “A retrospective review of the effects of PrTMS® on sleep improvement scores. Poster presented at the Clinical TMS Society’s Annual Meeting, Colorado Springs, CO (2023).
12. Hiroi R., et al. “Personalized rTMS (PrTMS^®) guided by qEEG provides improved outcome in a patient suffering from concussion, depression, and anxiety following a surfing accident. University of Hawaii Department of Psychiatry (2024).
13. Zmeykina E., et al. “Weak rTMS-induced electric fields produce neural entrainment in humans”. Scientific Reports (2020): 10.
14. Clancy KJ., et al. “Posttraumatic stress disorder is associated with α dysrhythmia across the visual cortex and the default mode network”. eNeuro 7.4 (2020).
15. Parks CJ., et al. “A retrospective review of patients with post-traumatic stress syndrome (PTSD) treated by personalized repetitive transcranial magnetic stimulation (PrTMS^®)”. Brain Stimulation 14.5 (2021): 1406.

Citation

Citation: Kavya Mohankumar., et al. “EEG-Spectra-Guided Personalized rTMS in PTSD with Co-occurring Psychiatric Disorders: A Case Series”. Acta Scientific Neurology 8.2 (2025): 03-09.

Copyright

Copyright: © 2025 Kavya Mohankumar., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.